Rapid risk assessment: Public health risks related to communicable diseases during the hajj 2019, Saudi Arabia, 9–14 August 2019
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
- Food- and waterborne diseases
- Hepatitis A
- Hepatitis B
- Mass gathering
- Meningococcal disease
- Middle East respiratory syndrome coronavirus
- Public health threat
- Saudi Arabia
- Travellers' health
- Vaccine preventable diseases
- Vector-borne disease
Rapid risk assessment: Chlamydia trachomatis false-negative test results by Aptima Combo 2 CT/NG assay (Hologic) in the EU/EEA, 2019
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia
This rapid risk assessment aims to assess the risk of XDR Neisseria gonorrhoeae spreading further in the EU/EEA and provide some options for response.
Rapid Risk Assessment: Potential public health risks related to communicable diseases at the WorldPride festival in Madrid, 23 June–2 July 2017
This rapid risk assessment reviews the health risks related to communicable diseases in the context of the WorldPride festival in Madrid, from 23 June to 2 July 2017.
Risk Assessment Brazil 2014 FIFA World Cup, 12 June–13 July 2014
The aim of this document is to assess the health risks related to communicable diseases and other health threats for European citizens during their stay in Brazil for the 2014 FIFA World Cup (‘Brazil 2014’) and the public health implications for European countries after the travellers’ return to Europe.
Risk assessment on change of testing requirements for partner donation of reproductive cells
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Risk assessment of HTLV-I/II transmission by tissue/cell transplantation
Following a request from the European Commission in August 2010, ECDC assessed the epidemiological history of Human T-lymphotropic Virus (HTLV) across the world, possible risks of HTLV transmission through transplantation of human tissues and cells, and possible measures to prevent such transmission.
Joint ECDC and EMCDDA rapid risk assessment: HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania
Most European countries reported no changes in the rate of newly diagnosed cases of HIV or HIV prevalence in IDU in 2011.
Risk assessment on xenotropic murine leukemia virus-related virus (XMRV) and its implications for blood donation
ECDC plays an important role in providing its stakeholders with scientific advice when requested. On 23 September 2010 ECDC received such a request from the European Commission’s DG SANCO (Directorate C – Public Health and Risk Assessment).